However, the frequent occurrence of adverse reactions to treatment, especially
nephrotoxicity, together with the small magnitude of the potential benefit, makes the risk/benefit of this therapeutic approach unacceptable (Level B recommendation).
Plasma exchange:
On the basis of consistent Class I, II, and III studies, plasma exchange is of little or no value in the treatment of progressive MS (Level A recommendation).